SPRY stock icon

ARS Pharmaceuticals

16.82 USD
+0.10
0.60%
Updated Oct 22, 10:48 AM EDT
1 day
0.60%
5 days
10.22%
1 month
19.38%
3 months
56.47%
6 months
104.87%
Year to date
201.43%
1 year
393.26%
5 years
177.56%
 

About: ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Employees: 24

0
Funds holding %
of 6,740 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

2,238% more call options, than puts

Call options by funds: $19.2M | Put options by funds: $821K

80% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 25

2.39% more ownership

Funds ownership: 62.17% [Q1] → 64.55% (+2.39%) [Q2]

5% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 22

1% more funds holding

Funds holding: 113 [Q1] → 114 (+1) [Q2]

13% less capital invested

Capital invested by funds: $613M [Q1] → $532M (-$80.8M) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$18
7%
upside
Avg. target
$26
57%
upside
High target
$30
78%
upside

7 analyst ratings

positive
100%
neutral
0%
negative
0%
Cantor Fitzgerald
Josh Schimmer
66% 1-year accuracy
40 / 61 met price target
78%upside
$30
Overweight
Reiterated
8 Oct 2024
Leerink Partners
Roanna Ruiz
100% 1-year accuracy
5 / 5 met price target
49%upside
$25
Outperform
Maintained
20 Sept 2024
Cantor Fitzgerald
Josh Schimmer
66% 1-year accuracy
40 / 61 met price target
78%upside
$30
Overweight
Reiterated
16 Sept 2024
Cantor Fitzgerald
Josh Schimmer
66% 1-year accuracy
40 / 61 met price target
78%upside
$30
Overweight
Reiterated
9 Sept 2024
Cantor Fitzgerald
Josh Schimmer
66% 1-year accuracy
40 / 61 met price target
78%upside
$30
Overweight
Initiated
20 Aug 2024

Financial journalist opinion

Based on 32 articles about SPRY published over the past 30 days

Charts implemented using Lightweight Charts™